HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: T-Cell Therapy For Seven Cancers Including Multiple Myeloma
Posted: Mar 24, 2017
Clinical Trial: T-Cell Therapy For Seven Cancers Including Multiple Myeloma image

A Phase I study is now open to test the safety and activity of several doses of each patients' NKR-2 cells in seven refractory cancers: five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).

The THINK study (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells. The trial will test three dose levels. At each dose, the patients will receive three successive administrations, two weeks apart, NKR-2 cells. The dose escalation part of the study will enroll up to 24 patients while the extension phase would enroll 86 additional patients.

There are 2 active sites for this trial: Roswell Park Cancer Institute and the University of Pittsburgh.

Learn more at the link below:

Cross-Cancer Clinical Trial

To find eligible clinical trials for your myeloma, click the link below: 

Find a Myeloma Clinical Trial on SparkCures

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube